Key clinical point: A dose of 100 mg guselkumab every 4/8 weeks (Q4W/Q8W) improved health-related quality of life (HRQoL) through 52 weeks in patients with psoriatic arthritis (PsA).
Major finding: A significantly higher proportion of patients receiving guselkumab Q4W/Q8W vs placebo reported minimally important differences in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index (56.0%/56.0% vs 43.4%; P < .006) and Visual Analog Scale (EQ-VAS) score (62.8%/63.5% vs 44.4%; P < .0001) at week 24, with >60% of patients reporting improvements at week 52.
Study details: Findings are from an analysis of the phase 3 DISCOVER 2 trial including 738 biologic-naive patients with active PsA and an inadequate response to standard treatments who were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.
Disclosures: This study was supported by Janssen, a subsidiary of Johnson and Johnson. Eight authors declared being employees of one of the subsidiaries of or owning stocks in Johnson and Johnson. The other authors reported ties with several sources.
Source: Curtis JR et al. The effect of guselkumab on general health state in biologic-naïve patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial. Adv Ther. 2022 (Aug 10). Doi: 10.1007/s12325-022-02269-0